Randomized, double-blind trial of exifone versus cognitive problems in Parkinson's disease.
Exifone is a novel substance of the benzophenone group that possesses potent scavenging properties. Initial findings demonstrate beneficial effects on age-related cognitive disorders. In this double-blind clinical trial versus placebo, the efficacy of 2 dosages (600 and 1200 mg/d) was evaluated with regard to Parkinson's disease (PD)-related cognitive disorders, for which there is increasing suspicion of a free-radicals origin. Despite disparities between the treatment groups as assessed by validated scales and subtests, and a considerable placebo effect on main parameters, both dose levels of exifone produced statistically significant improvement of the cognitive items most commonly impaired by PD: immediate recall, naming of objects presented, spatiotemporal orientation, and calculation. These properties suggest a new slot for exifone in the range of therapeutics available.
Allain
H
H
Service de Neurologie, Hôpital de Pontchaillou, Rennes, France.
Denmat
J
J
Bentue-Ferrer
D
D
Milon
D
D
Pignol
P
P
Reymann
J M
JM
Pape
D
D
Sabouraud
O
O
Van den Driessche
J
J
D000368:Aged; D001577:Benzophenones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D011897:Random Allocation
D001577:Benzophenones; D011619:Psychotropic Drugs; C052932:exifone